STCube Inc Cash Flow Conversion Efficiency
STCube Inc cash flow conversion efficiency. Based on the latest financial reports, STCube Inc (052020) has a cash flow conversion efficiency ratio of -0.065x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.92 Billion ≈ $-2.65 Million USD) by net assets (₩60.29 Billion ≈ $40.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of STCube Inc (2009–2025)
Cash flow conversion efficiency of STCube Inc from 2009 to 2025. This chart illustrates how STCube Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest STCube Inc stock price today for real-time trading data and today's change.
STCube Inc Cash Flow Conversion Ratio Explained
STCube Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
STCube Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STCube Inc ranked by their cash flow conversion efficiency. Also see 052020 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kangstem Biotech Co. Ltd
KQ:217730
|
-0.087x |
|
Bellevue Group AG
SW:BBN
|
0.150x |
|
Norsk Titanium AS
OL:NTI
|
-0.732x |
|
UVAT Technology Co Ltd
TWO:3580
|
0.047x |
|
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
|
-0.050x |
|
Vardhman Holdings Limited
NSE:VHL
|
0.000x |
|
Excel Industries Limited
NSE:EXCELINDUS
|
0.010x |
|
Aroa Biosurgery Ltd
AU:ARX
|
0.045x |
Annual Cash Flow Conversion Efficiency for STCube Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of STCube Inc from 2009 to 2025. Review cash generation quality of STCube Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩72.12 Billion ≈ $48.88 Million |
₩-19.78 Billion ≈ $-13.40 Million |
-0.274x | -10.84% |
| 2024-12-31 | ₩94.28 Billion ≈ $63.89 Million |
₩-23.32 Billion ≈ $-15.80 Million |
-0.247x | +64.51% |
| 2023-12-31 | ₩35.31 Billion ≈ $23.93 Million |
₩-24.61 Billion ≈ $-16.68 Million |
-0.697x | -121.89% |
| 2022-12-31 | ₩51.22 Billion ≈ $34.71 Million |
₩-16.09 Billion ≈ $-10.90 Million |
-0.314x | +70.39% |
| 2021-12-31 | ₩16.16 Billion ≈ $10.95 Million |
₩-17.15 Billion ≈ $-11.62 Million |
-1.061x | -271.33% |
| 2020-12-31 | ₩36.03 Billion ≈ $24.41 Million |
₩-10.29 Billion ≈ $-6.97 Million |
-0.286x | -4165.71% |
| 2019-12-31 | ₩28.82 Billion ≈ $19.53 Million |
₩-192.99 Million ≈ $-130.79K |
-0.007x | +95.65% |
| 2018-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.154x | +74.13% |
| 2017-12-31 | ₩19.12 Billion ≈ $12.96 Million |
₩-11.38 Billion ≈ $-7.71 Million |
-0.595x | -386.91% |
| 2016-12-31 | ₩29.24 Billion ≈ $19.81 Million |
₩6.07 Billion ≈ $4.11 Million |
0.207x | +203.54% |
| 2015-12-31 | ₩20.91 Billion ≈ $14.17 Million |
₩-4.19 Billion ≈ $-2.84 Million |
-0.200x | -182.38% |
| 2012-12-31 | ₩8.79 Billion ≈ $5.96 Million |
₩2.14 Billion ≈ $1.45 Million |
0.243x | +203.88% |
| 2011-12-31 | ₩9.97 Billion ≈ $6.76 Million |
₩-2.33 Billion ≈ $-1.58 Million |
-0.234x | -74.55% |
| 2010-12-31 | ₩11.74 Billion ≈ $7.95 Million |
₩-1.57 Billion ≈ $-1.07 Million |
-0.134x | -244.26% |
| 2009-12-31 | ₩16.63 Billion ≈ $11.27 Million |
₩1.55 Billion ≈ $1.05 Million |
0.093x | -- |
About STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more